Kanjinti 150 mg

KANJINTI 150 MG is a powder for solution used in intravenous therapy. It contains trastuzumab, a monoclonal antibody indicated for certain types of cancer. This medication is manufactured by Amgen Canada Inc.

KANJINTI 150 MG is primarily used in the treatment of specific types of cancer, particularly those that involve the HER2 protein. It is often prescribed for breast cancer and gastric cancer that overexpress this protein. The medication works by targeting and blocking the growth of cancer cells, helping to slow or stop their progression. Patients should consult their healthcare provider to determine if KANJINTI is suitable for their condition.

Common effects of KANJINTI 150 MG may include fatigue, nausea, and fever. Some patients might experience pain at the injection site or a general feeling of weakness. Severe side effects are rare but can occur, and patients should report any unusual symptoms to their healthcare provider immediately.

KANJINTI 150 MG should be handled with care and administered by a healthcare professional. It is important to follow the prescribed dosage and administration instructions closely. Patients with a history of heart problems should discuss this with their doctor before starting treatment. Always store the medication as directed to maintain its efficacy.

KANJINTI 150 MG may interact with other medications, particularly those that affect the immune system or heart function. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol and certain foods may also interact with KANJINTI, so patients should follow their doctor's advice regarding lifestyle modifications.